Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
Read the full article on CNBC
Read Full Article →